Dapagliflozin Improves Left Ventricular Myocardial Longitudinal Function in Patients With Type 2 Diabetes

MLA

Ify R. Mordi, et al. “Dapagliflozin Improves Left Ventricular Myocardial Longitudinal Function in Patients With Type 2 Diabetes.” JACC: Cardiovascular Imaging, vol. 14, Feb. 2021, pp. 503–04. EBSCOhost, https://doi.org/10.1016/j.jcmg.2020.07.025.

APA

Ify R. Mordi, Chim C. Lang, Prasad Guntur Ramkumar, Alexander J.M. Brown, Rory J. McCrimmon, J. Graeme Houston, Allan D. Struthers, & Stephen J. Gandy. (2021). Dapagliflozin Improves Left Ventricular Myocardial Longitudinal Function in Patients With Type 2 Diabetes. JACC: Cardiovascular Imaging, 14, 503–504. https://doi.org/10.1016/j.jcmg.2020.07.025

Chicago

Ify R. Mordi, Chim C. Lang, Prasad Guntur Ramkumar, Alexander J.M. Brown, Rory J. McCrimmon, J. Graeme Houston, Allan D. Struthers, and Stephen J. Gandy. 2021. “Dapagliflozin Improves Left Ventricular Myocardial Longitudinal Function in Patients With Type 2 Diabetes.” JACC: Cardiovascular Imaging 14 (February): 503–4. doi:10.1016/j.jcmg.2020.07.025.